Healing Properties of Epidermal Growth Factor and Tocotrienol-Rich Fraction in Deep Partial-Thickness Experimental Burn Wounds

Guo, Han; Hamid, Roslida Abd; Ali, Razana Mohd; Chang, Sui Kiat; Rahman, Md. Habibur; Zainal, Zaida; Khaza’ai, Huzwah

doi:10.3390/antiox9020130

Cited by 13 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary goal of burn treatment is effective wound management, which largely determines the survival and prognosis of patients with severe burns [4,5]. Although the skin has the ability to heal itself, severe burns require a variety of interventions, such as healing drugs [6,7], debridement [8,9], and skin grafts [10,11]. However, for severe burns, skin grafts can cause harmful psychological effects [12] and severe disfigurement of the donor's skin [13].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of stem cell therapy for burn wounds: a systematic review and meta-analysis of preclinical studies

Xia

Merwe

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Burns remain a serious public health problem with high morbidity and mortality rates worldwide. Although there are various treatment options available, there is no consensus on the best treatment for severe burns as of yet. Stem cell therapy has a bright prospect in many preclinical studies of burn wounds. The systematic review was performed for these preclinical studies to assess the efficacy and possible mechanisms of stem cells in treating burn wounds. Methods Twenty-two studies with 595 animals were identified by searching PubMed, EMBASE, Web of Science, and Cochrane Library databases from inception to 13 May 2020. In addition, a manual search of references of studies was performed to obtain potential studies. No language or time restrictions were enforced. RevMan 5.3 was used for all data analysis. Results The overall meta-analysis showed that stem cell therapy significantly improved burn healing rate (SMD 3.06, 95% CI 1.98 to 4.14), irrespective of transplant type, burn area, and treatment method in the control group. Subgroup analyses indicated that hair follicle stem cells seemed to exert more beneficial effects on animals with burn wounds (SMD 7.53, 95% CI 3.11 to 11.95) compared with other stem cells. Furthermore, stem cell therapy seemed to exert more beneficial effects on burn wounds with second-degree (SMD 7.53, 95% CI 3.11 to 11.95) compared with third-degree (SMD 2.65, 95% CI 1.31 to 4.00). Conclusions Meta-analysis showed that stem cell therapy exerts a healing function for burn wounds, mainly through angiogenesis and anti-inflammatory actions. These findings also demonstrate the need for considering variations in future clinical studies using stem cells to treat a burn wound in order to maximize the effectiveness. In general, stem cells can potentially become a novel therapy candidate for burn wounds.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of stem cell therapy for burn wounds: a systematic review and meta-analysis of preclinical studies

Xia

Merwe

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Additionally, lowering of lipid peroxidation and nitrite levels were observed indicating reduced oxidative stress. TRF together with EGF presents a new therapeutic combination in the treatment of burn wounds 301 …”

Section: Tocotrienol Activity In Systemic Diseasementioning

confidence: 99%

Revisiting the therapeutic potential of tocotrienol

2022

View full text Add to dashboard Cite

The therapeutic potential of the tocotrienol group stems from its nutraceutical properties as a dietary supplement. It is largely considered to be safe when consumed at low doses for attenuating pathophysiology as shown by animal models, in vitro assays, and ongoing human trials. Medical researchers and the allied sciences have experimented with tocotrienols for many decades, but its therapeutic potential was limited to adjuvant or concurrent treatment regimens. Recent studies have focused on targeted drug delivery by enhancing the bioavailability through carriers, self‐sustained emulsions, nanoparticles, and ethosomes. Epigenetic modulation and computer remodeling are other means that will help increase chemosensitivity. This review will focus on the systemic intracellular anti‐cancer, antioxidant, and anti‐inflammatory mechanisms that are stimulated and/or regulated by tocotrienols while highlighting its potent therapeutic properties in a diverse group of clinical diseases.

show abstract

“…Antioxidants, such as zinc and n-acetylcysteine, are used in COVID-19 patients to reduce inflammation [ 36 , 37 ]. Recent studies showed that several growth factors included in aaPRP, such as EGF [ 38 ] and IGF-1 [ 39 ], also have antioxidant effects. In addition, IGF-1 and hepatocyte growth factors were also known as antifibrogenic agents that help reduce inflammation-mediated fibrosis in the lungs of COVID-19 patients [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Karina

Rosliana

Rosadi

et al. 2021

International Journal of Inflammation

View full text Add to dashboard Cite

Background. The outbreak of Coronavirus Disease 2019 (COVID-19) has been increasing rapidly. This disease causes an increase in proinflammatory cytokine production that leads to cytokine storm or cytokine release syndrome (CRS). Autologous activated platelet-rich plasma (aaPRP) contains various types of growth factors and anti-inflammatory cytokines that may have the potential to suppress CRS. This study of phase I/II trial was aimed to evaluate the safety and efficacy of aaPRP to treat severe COVID-19 patients. Methods. A total of 10 severe COVID-19 patients from Koja Regional Public Hospital (Koja RPH) were admitted to the intensive care unit (ICU). All patients received aaPRP administration three times. Primary outcomes involving the duration of hospitalization, oxygen needs, time of recovery, and mortality were observed. Secondary outcomes involving C-reactive protein (CRP), neutrophil, lymphocyte, and lymphocyte-to-CRP (LCR) and neutrophil-lymphocyte ratio (NLR) were analyzed. Results. All patients were transferred to the ICU with a median duration of 9 days. All patients received oxygen at enrollment and nine of ten patients recovered from the ICU and transferred to the ward room. There was one patient who passed away in the ICU due to heart failure. The results of secondary outcomes showed that CRP value and lymphocytes counts were significantly decreased while neutrophils, LCR, and NLR were slightly increased after aaPRP administration. Conclusions. Our results of the phase I/II trial demonstrated that the use of aaPRP in severe COVID-19 patients was safe and not associated with serious adverse events, which showed that aaPRP was a promising adjunctive therapy for severe COVID-19 patients.

show abstract

Healing Properties of Epidermal Growth Factor and Tocotrienol-Rich Fraction in Deep Partial-Thickness Experimental Burn Wounds

Cited by 13 publications

References 34 publications

Efficacy of stem cell therapy for burn wounds: a systematic review and meta-analysis of preclinical studies

Efficacy of stem cell therapy for burn wounds: a systematic review and meta-analysis of preclinical studies

Revisiting the therapeutic potential of tocotrienol

Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Contact Info

Product

Resources

About